Advertisement
Canada markets open in 5 hours 27 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7312
    +0.0014 (+0.20%)
     

  • CRUDE OIL

    83.06
    +0.25 (+0.30%)
     

  • Bitcoin CAD

    87,607.20
    -3,763.58 (-4.12%)
     

  • CMC Crypto 200

    1,382.47
    -0.10 (-0.01%)
     

  • GOLD FUTURES

    2,338.40
    0.00 (0.00%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,463.25
    -201.25 (-1.14%)
     

  • VOLATILITY

    16.23
    +0.26 (+1.63%)
     

  • FTSE

    8,079.32
    +38.94 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6816
    -0.0003 (-0.04%)
     

Helix BioPharma Corp. Announces Management Change

Marketwired

RICHMOND HILL, ONTARIO--(Marketwired - Dec. 1, 2017) - Helix BioPharma Corp. (HBP.TO) (HBP.TO), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced Steve Demas, its Chief Operating Officer, has resigned due to personal reasons. "I want to thank Steve on behalf of Helix for his significant contribution to the Company," said Heman Chao, Chief Executive Officer. "I wish him the best in his future endeavors".

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".